Dynamic Clinical Success Rates for Drugs in the 21st Century

Ying Zhou, Yintao Zhang, Zhen Chen, Shijie Huang, Yinghong Li, Jianbo Fu, Hongning Zhang, Donghai Zhao, Xichen Lian, Yuan Zhou, Xinyi Shen, Yunqing Qiu, Lianyi Han, Feng Zhu
{"title":"Dynamic Clinical Success Rates for Drugs in the 21st Century","authors":"Ying Zhou, Yintao Zhang, Zhen Chen, Shijie Huang, Yinghong Li, Jianbo Fu, Hongning Zhang, Donghai Zhao, Xichen Lian, Yuan Zhou, Xinyi Shen, Yunqing Qiu, Lianyi Han, Feng Zhu","doi":"10.1101/2024.02.26.24303388","DOIUrl":null,"url":null,"abstract":"In clinical drug development, two fundamental questions remain unanswered: what is the success rate of drugs in clinical trial? how does such rate change over time? Herein, a systematic analysis on the dynamic change of drugs' clinical success rates (ClinSRs) using data from 20,398 clinical trial pipelines of 9,682 unique molecular entities during the past two decades was presented. Our analysis discovered that ClinSRs had been declining since the beginning of 21st century, and hit the bottom in recent years even substantially lower than previous estimates. In-depth assessments further reported great variation among the ClinSRs of various diseases, developmental strategies, and drug modalities. A platform ClinSR.org (http://ClinSR.idrblab.org/) was finally constructed online to enable the illustration of how ClinSR dynamically changes over time, automated update of ClinSR for the coming decade, and customized calculation of ClinSRs for any drug group of interest. In sum, this study met the critical demand for accurate, timely and persistent assessment of ClinSR, for now and the future, to aid pharmaceutical and economic decision making.","PeriodicalId":501447,"journal":{"name":"medRxiv - Pharmacology and Therapeutics","volume":"2016 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.02.26.24303388","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In clinical drug development, two fundamental questions remain unanswered: what is the success rate of drugs in clinical trial? how does such rate change over time? Herein, a systematic analysis on the dynamic change of drugs' clinical success rates (ClinSRs) using data from 20,398 clinical trial pipelines of 9,682 unique molecular entities during the past two decades was presented. Our analysis discovered that ClinSRs had been declining since the beginning of 21st century, and hit the bottom in recent years even substantially lower than previous estimates. In-depth assessments further reported great variation among the ClinSRs of various diseases, developmental strategies, and drug modalities. A platform ClinSR.org (http://ClinSR.idrblab.org/) was finally constructed online to enable the illustration of how ClinSR dynamically changes over time, automated update of ClinSR for the coming decade, and customized calculation of ClinSRs for any drug group of interest. In sum, this study met the critical demand for accurate, timely and persistent assessment of ClinSR, for now and the future, to aid pharmaceutical and economic decision making.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
21 世纪药物的动态临床成功率
在临床药物开发过程中,有两个基本问题仍未得到解答:药物的临床试验成功率是多少?本文利用过去二十年中 20,398 个临床试验管线中 9,682 个独特分子实体的数据,对药物临床成功率(ClinSRs)的动态变化进行了系统分析。我们的分析发现,自 21 世纪初以来,药物临床成功率一直在下降,近年来更是跌至谷底,甚至大大低于之前的估计值。深入评估进一步表明,各种疾病、发展战略和药物模式的 ClinSRs 之间存在巨大差异。最后,我们在网上建立了一个平台 ClinSR.org (http://ClinSR.idrblab.org/),以说明 ClinSR 如何随时间动态变化,自动更新未来十年的 ClinSR,并为任何感兴趣的药物组定制计算 ClinSR。总之,这项研究满足了当前和未来对 ClinSR 进行准确、及时和持续评估的迫切需求,从而有助于制药和经济决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Tucaresol: An Oral Candidate Drug With Two Distinct Antiviral Mechanisms. Comparative Risk of the Onset of Atrial Fibrillation after Icosapent Ethyl versus Omega-3–Acid-Ethyl-Esters Adjuvant to Statins A Novel Maxillofacial Technology for Drug Administration-A Randomized Controlled Trial Using Metronidazole. Protective Effects of Psychiatric Medications against COVID-19 Mortality Before Vaccines Anti-cancer effect of memantine as adjunctive therapy in metastatic colon cancer: A pilot randomized controlled clinical trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1